Lyme Disease Clinical Trial Pipeline Advances with Over 7 Companies
A new report details the ongoing development of Lyme disease treatments, with more than seven companies actively pursuing new therapies. The analysis covers pipeline drugs in clinical and pre-clinical stages.
The development pipeline for Lyme disease treatments is showing increased activity, with over seven companies engaged in advancing new therapeutic options. DelveInsight's "Lyme Disease Pipeline Insight 2026" report highlights these efforts, covering drugs in both clinical and non-clinical stages of development.
The report specifically notes Pfizer's initiation of a Phase 2 study in September 2026, designed to assess the safety and immunogenicity of two different vaccination schedules. This study will enroll 600 healthy participants aged 5 to 65.
Companies identified as active players in the Lyme disease pipeline include Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, and Aegis Life. Valneva's vaccine candidate, VLA15, is highlighted as the sole active vaccine program in clinical development for Lyme disease. Pfizer is collaborating with Valneva on the late-stage development and commercialization of VLA15.
Lyme disease, the most common tick-borne illness in the United States, is caused by Borrelia bacteria. Symptoms can include fever, headache, fatigue, and a characteristic rash. Early diagnosis and antibiotic treatment are crucial for managing the infection, which can affect joints, the heart, and the nervous system if left untreated.